KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Payables (2016 - 2025)

NovoCure (NVCR) has disclosed Payables for 12 consecutive years, with $122.2 million as the latest value for Q4 2025.

  • Quarterly Payables fell 81.57% to $122.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.2 million through Dec 2025, down 81.57% year-over-year, with the annual reading at $122.2 million for FY2025, 81.57% down from the prior year.
  • Payables hit $122.2 million in Q4 2025 for NovoCure, down from $679.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $679.5 million in Q3 2025 to a low of $52.7 million in Q1 2021.
  • Historically, Payables has averaged $224.9 million across 5 years, with a median of $83.4 million in 2023.
  • Biggest five-year swings in Payables: skyrocketed 714.19% in 2024 and later tumbled 81.57% in 2025.
  • Year by year, Payables stood at $72.6 million in 2021, then grew by 17.35% to $85.2 million in 2022, then increased by 10.79% to $94.4 million in 2023, then skyrocketed by 602.66% to $663.2 million in 2024, then crashed by 81.57% to $122.2 million in 2025.
  • Business Quant data shows Payables for NVCR at $122.2 million in Q4 2025, $679.5 million in Q3 2025, and $663.5 million in Q2 2025.